How common are liver enzyme increases with tigecycline?

What is the incidence of liver enzyme elevations with tigecycline?

Tigecycline, a broad-spectrum antibiotic, has been associated with liver enzyme elevations in some patients. According to the drug's safety information, [1] liver enzyme elevations, primarily elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported in up to 14% of patients receiving tigecycline.

Why are liver enzyme elevations a concern with tigecycline?

Liver enzyme elevations can be a sign of liver damage or injury, which may be a rare but potentially serious side effect of tigecycline. In some cases, these elevations may be associated with more severe outcomes, such as hepatitis or liver failure. Monitoring liver function is recommended in patients receiving tigecycline, especially those with pre-existing liver conditions.

Can tigecycline be safely used in patients at high risk of liver enzyme elevations?

Patients with pre-existing liver disease, alcoholism, or other liver conditions may be at increased risk of developing liver enzyme elevations with tigecycline. However, the benefits and risks of tigecycline should be carefully weighed in these patients, and close monitoring of liver function is essential.

How does the incidence of liver enzyme elevations with tigecycline compare with other antibiotics?

The comparative incidence of liver enzyme elevations with tigecycline is not well established. However, according to the US Food and Drug Administration (FDA), [2] other antibiotics, such as linezolid and minocycline, have also been associated with liver enzyme elevations.

What measures can be taken to minimize the risk of liver enzyme elevations with tigecycline?

Monitoring liver function is essential in patients receiving tigecycline. Additionally, patients with pre-existing liver conditions or other risk factors should be carefully selected for treatment with tigecycline, and the benefits and risks of the antibiotic should be carefully weighed.

References:

[1] DrugPatentWatch.com, Tigecycline: Safety Information.

[2] FDA, Drug Safety Communication: FDA Requires Labeling Changes for Antibiotic Linezolid Due to Risk of Serious Liver Injury.

Note: This response uses DrugPatentWatch.com as a source and provides a concise synthesis of key points related to the question, while covering adjacent search pathways and related subtopics.